File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin

TitleTreatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin
Authors
Issue Date1989
Citation
Australian Paediatric Journal, 1989, v. 25 n. 5, p. 274-278 How to Cite?
AbstractFourteen aptients with precocious puberty were treated for 1-3 years with 900-1800 μg/day of intranasal (i.n.) Buserelin. The peak luteinizing hormone and follicle-stimulating hormone responses to intravenous luteinizing hormone-releasing hormone were reduced significantly 4 weeks after starting treatment and remained suppressed while the patients were on treatment. Two patients were withdrawn because of drug non-compliance. Three patients showed regression of pubertal changes, four patients showed no progression and five patients showed progression of breast size or pubic hair staging after 1.5-2 years of treatment. Treatment was changed to the subcutaneous route in two patients because of hormonal escape and accelerated skeletal maturation. The mean growth velocity decreased from 10.78 cm/year (s.e.m. = 0.64) to 7.06 cm/year (s.e.m. = 0.85) after 1 year of treatment (P < 0.005). After an increase in dosage (from 900 μg/day to 1800 μg/day) in most patients, further significant falls in growth velocity to 5.29 cm/year (s.e.m. = 0.45), 4.63 cm/year (s.e.m. = 0.8) and 5.06 cm/year (s.e.m. = 0.5) were observed at 18, 24 and 30 months, respectively, compared with the pretreatment value (P < 0.001). With treatment, the increased rate of skeletal maturation normalized. In 10 patients who had completed 2 years of treatment, the height standard deviation score for bone age improved from a pretreatment value of -2.42 ± 0.42 to -1.6 ± 0.42 after 2 years of treatment (P < 0.01), indicating an improvement in height prognosis. It is concluded that i.n. Buserelin at a dose of 1800 μg/day is effective in the treatment of most but not all patients with precocious puberty.
Persistent Identifierhttp://hdl.handle.net/10722/170237
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLow, LCKen_HK
dc.contributor.authorWang, Cen_HK
dc.contributor.authorCheung, PTen_HK
dc.contributor.authorChan, FLen_HK
dc.date.accessioned2012-10-30T06:06:53Z-
dc.date.available2012-10-30T06:06:53Z-
dc.date.issued1989en_HK
dc.identifier.citationAustralian Paediatric Journal, 1989, v. 25 n. 5, p. 274-278en_HK
dc.identifier.issn0004-993Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/170237-
dc.description.abstractFourteen aptients with precocious puberty were treated for 1-3 years with 900-1800 μg/day of intranasal (i.n.) Buserelin. The peak luteinizing hormone and follicle-stimulating hormone responses to intravenous luteinizing hormone-releasing hormone were reduced significantly 4 weeks after starting treatment and remained suppressed while the patients were on treatment. Two patients were withdrawn because of drug non-compliance. Three patients showed regression of pubertal changes, four patients showed no progression and five patients showed progression of breast size or pubic hair staging after 1.5-2 years of treatment. Treatment was changed to the subcutaneous route in two patients because of hormonal escape and accelerated skeletal maturation. The mean growth velocity decreased from 10.78 cm/year (s.e.m. = 0.64) to 7.06 cm/year (s.e.m. = 0.85) after 1 year of treatment (P < 0.005). After an increase in dosage (from 900 μg/day to 1800 μg/day) in most patients, further significant falls in growth velocity to 5.29 cm/year (s.e.m. = 0.45), 4.63 cm/year (s.e.m. = 0.8) and 5.06 cm/year (s.e.m. = 0.5) were observed at 18, 24 and 30 months, respectively, compared with the pretreatment value (P < 0.001). With treatment, the increased rate of skeletal maturation normalized. In 10 patients who had completed 2 years of treatment, the height standard deviation score for bone age improved from a pretreatment value of -2.42 ± 0.42 to -1.6 ± 0.42 after 2 years of treatment (P < 0.01), indicating an improvement in height prognosis. It is concluded that i.n. Buserelin at a dose of 1800 μg/day is effective in the treatment of most but not all patients with precocious puberty.en_HK
dc.languageengen_US
dc.relation.ispartofAustralian Paediatric Journalen_HK
dc.subject.meshAdministration, Intranasalen_US
dc.subject.meshBuserelin - Administration & Dosageen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshGonadal Steroid Hormones - Blooden_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshLong-Term Careen_US
dc.subject.meshMaleen_US
dc.subject.meshPuberty, Precocious - Blood - Drug Therapyen_US
dc.subject.meshSexual Maturation - Drug Effectsen_US
dc.titleTreatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelinen_HK
dc.typeArticleen_HK
dc.identifier.emailLow, LCK: lcklow@hkucc.hku.hken_HK
dc.identifier.emailCheung, PT: ptcheung@hku.hken_HK
dc.identifier.authorityLow, LCK=rp00337en_HK
dc.identifier.authorityCheung, PT=rp00351en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2511831-
dc.identifier.scopuseid_2-s2.0-0024454335en_HK
dc.identifier.volume25en_HK
dc.identifier.issue5en_HK
dc.identifier.spage274en_HK
dc.identifier.epage278en_HK
dc.identifier.isiWOS:A1989AZ03400006-
dc.identifier.scopusauthoridLow, LCK=7007049461en_HK
dc.identifier.scopusauthoridWang, C=7501631357en_HK
dc.identifier.scopusauthoridCheung, PT=7202595465en_HK
dc.identifier.scopusauthoridChan, FL=7202586444en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats